Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing trazodone hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing trazodone are listed in tablet and solution forms. No trazodone product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Trazodone is a serotonin antagonist and reuptake inhibitor antidepressant; compounding pharmacies prepare it as oral liquids and capsules by prescription.
Trazodone is a triazolopyridine antidepressant. Its antidepressant action is not fully understood; it inhibits serotonin reuptake and blocks 5-HT2 receptors, and StatPearls notes it also blocks histamine H1 and alpha-1 adrenergic receptors, which accounts for its sedating effect. Manufactured trazodone hydrochloride tablets (for example TruPharma) and Raldesy oral solution (Validus Pharmaceuticals) are FDA-approved to treat major depressive disorder in adults. Trazodone is not FDA-approved for sleep disorders, although it is used off-label for insomnia. Because a manufactured oral solution now exists, a prescriber may order trazodone compounded only when a patient needs a strength, flavor or dosage form that is not manufactured, or a vehicle free of an ingredient in Raldesy, such as sorbitol or propylene glycol. Compounded preparations are not FDA-approved and require a prescription.
Trazodone carries an FDA boxed warning: antidepressants increased suicidal thoughts and behaviors in children and young adults in short-term studies, and it is not approved for children; watch for worsening mood or suicidal thoughts. Do not take it with, or within 14 days of, an MAO inhibitor, including linezolid or IV methylene blue. Other serious risks include serotonin syndrome with other serotonergic drugs, QT prolongation and abnormal heart rhythms, low blood pressure on standing and fainting, bleeding with aspirin, NSAIDs or blood thinners, priapism, mania, angle-closure glaucoma and low sodium. Strong CYP3A4 inhibitors raise its levels, and it adds to alcohol and sedatives. Do not stop it suddenly. Published studies over decades have not identified a link to major birth defects or miscarriage, and LactMed reports low milk levels. Get emergency care for an erection lasting more than 4 hours. For other side effects, talk to your prescriber or pharmacist.
Trazodone inhibits the serotonin transporter and antagonizes 5-HT2A and 5-HT2C receptors, with H1 and alpha-1 blockade; StatPearls attributes low-dose sedation to 5-HT2A, H1 and alpha-1 antagonism. Per the label, peak plasma levels occur about 1 hour after a fasting dose or 2 hours with food, protein binding is 89 to 95 percent, CYP3A4 forms the active metabolite m-chlorophenylpiperazine (mCPP), and under 1 percent is excreted unchanged in urine. StatPearls reports oral bioavailability near 100 percent and a terminal half-life of 5 to 9 hours. Labeled indication: major depressive disorder in adults (trazodone tablets; Raldesy oral solution). StatPearls lists off-label uses including insomnia, anxiety and PTSD-related nightmares; none of these is an FDA-approved indication. Dosing is per prescriber, with a gradual taper on discontinuation. Avoid combining with QT-prolonging drugs; with strong CYP3A4 inhibitors consider a lower dose, and inducers such as carbamazepine reduce levels. Measure digoxin or phenytoin levels and monitor INR with warfarin. Monitor for suicidality, serotonin syndrome, orthostasis, sodium in older adults, and liver function at baseline and periodically (StatPearls). Screen for personal or family history of bipolar disorder. Trazodone is not a controlled substance.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
